Literature DB >> 23467015

Lower mortality and inflammation from post-transplantation encapsulating peritoneal sclerosis compared to the classical form.

Sayed M Habib1, Mario R Korte, Michiel G H Betjes.   

Abstract

BACKGROUND: Encapsulating peritoneal sclerosis (EPS) may occur after kidney transplantation (post-transplantation EPS) or may be diagnosed during or after peritoneal dialysis treatment (classical EPS). The aim of the present study was to investigate to what extent both EPS entities differ in clinical presentation, radiological findings, outcome, and the systemic inflammatory response, as measured by plasma C-reactive protein (CRP) levels both prior to and after EPS diagnosis.
METHODS: We performed a retrospective analysis of 15 post-transplantation EPS and 19 classical EPS patients who were diagnosed at seven hospitals in the Netherlands between January 1, 2000, and January 1, 2011.
RESULTS: There were no inter-group differences in age, duration of peritoneal dialysis, clinical presentation, or radiology findings at diagnosis. Post-transplantation patients had experienced a lower number of peritonitis episodes per patient-year (0.2 (0.0-0.4) vs. 0.7 (0.3-1.2), p = 0.01) with a longer interval between the last peritonitis and EPS diagnosis (18.1 (4.6-34.3) vs. 4.4 (0.89-13.78) months, p = 0.01). Post-transplantation EPS patients showed a remarkably lower mortality rate (40.0 vs. 84.2%, p < 0.05). In both groups a pattern of elevated CRP values was observed, increasing within the year before EPS diagnosis. In the post-transplantation group the median CRP level at diagnosis was lower (56.0 vs. 144.50 mg/l, p < 0.05) than in the classical EPS group.
CONCLUSION: Post-transplantation EPS has a similar clinical presentation as classical EPS but with a lower systemic inflammatory response and better outcome.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23467015     DOI: 10.1159/000348267

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  6 in total

1.  Successful treatment of encapsulating peritoneal sclerosis by hemodialysis and peritoneal lavage using dialysate containing dissolved hydrogen.

Authors:  Hiroyuki Terawaki; Hirofumi Nakano; Wan-Jun Zhu; Masaaki Nakayama
Journal:  Perit Dial Int       Date:  2015 Jan-Feb       Impact factor: 1.756

2.  mTOR inhibitors for medical treatment of post-transplantation encapsulating peritoneal sclerosis: a favourable single center experience.

Authors:  Maria Messina; Claudia Ariaudo; Alberto Mella; Vincenzo Cantaluppi; Giuseppe P Segoloni; Luigi Biancone
Journal:  J Nephrol       Date:  2015-01-14       Impact factor: 3.902

3.  Encapsulating peritoneal sclerosis in an Italian center: thirty year experience.

Authors:  Valerio Vizzardi; Massimo Sandrini; Silvia Zecchini; Sara Ravera; Luigi Manili; Giovanni Cancarini
Journal:  J Nephrol       Date:  2015-10-31       Impact factor: 3.902

4.  CD4-Positive T Cells and M2 Macrophages Dominate the Peritoneal Infiltrate of Patients with Encapsulating Peritoneal Sclerosis.

Authors:  Sayed M Habib; Alferso C Abrahams; Mario R Korte; Robert Zietse; Lisette L de Vogel; Walther H Boer; Amélie Dendooven; Marian C Clahsen-van Groningen; Michiel G H Betjes
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

5.  Histological and clinical findings in patients with post-transplantation and classical encapsulating peritoneal sclerosis: a European multicenter study.

Authors:  Joerg Latus; Sayed M Habib; Daniel Kitterer; Mario R Korte; Christoph Ulmer; Peter Fritz; Simon Davies; Mark Lambie; M Dominik Alscher; Michiel G H Betjes; Stephan Segerer; Niko Braun
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

6.  Vascular Endothelial Cell Injury Is an Important Factor in the Development of Encapsulating Peritoneal Sclerosis in Long-Term Peritoneal Dialysis Patients.

Authors:  Mitsuhiro Tawada; Yasuhiko Ito; Chieko Hamada; Kazuho Honda; Masashi Mizuno; Yasuhiro Suzuki; Fumiko Sakata; Takeshi Terabayashi; Yoshihisa Matsukawa; Shoichi Maruyama; Enyu Imai; Seiichi Matsuo; Yoshifumi Takei
Journal:  PLoS One       Date:  2016-04-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.